Goodwin Procter LLP and Dechert advised Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX) announced its acquisition of Minerva Neurosciences (Nasdaq: NERV) royalty interest in seltorexant…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
